IL18 and endothelial dysfunction: Given the implications of the IL-18/IL-18BP pathway in endothelial dysfunction [31,32] and the fact that IL-18 may be released from dying endothelium [11], high IL-18 levels in patients undergoing alloSCT may also reflect endothelial distress caused by the underlying hematologic malignancy and/or the previous antineoplastic treatment.